MOUNT PLEASANT, S.C., Oct. 4 /PRNewswire-FirstCall/ -- Maxxon Inc. announced that it has filed a PCT (Patent Cooperation Treaty) application for its proprietary ReVac safety syringe, which puts the application on file in 133 countries worldwide with an effective filing date of September 21, 2005. Maxxon has also filed for additional patent protection in Taiwan.
Maxxon Inc. President Ron Wheet announced, “Protecting our proprietary technology gives us a significant advantage over our competitors in the safety syringe market; this gives us two patents protecting our technology. Our ReVac product is designed to incorporate all of the features that medical professionals want: it’s easy to use, easy to read, safe, efficiently designed for one-handed use, and the price is significantly less expensive than other safety syringes on the market. Our product employs proprietary vacuum force technology to cause the needle to retract into the barrel of the syringe after an injection is administered. We feel that our patented vacuum force design is the reason we can offer such significant clinical advantages to our customers, and at our price point we are very optimistic about the future success of our product.”
About Maxxon Inc.:
Maxxon operates in the safety-engineered medical devices (SEMDs) arena. Its products include the ReVac Safety Syringe, Auto-Retractable Safety Scalpel with Permanent Lock and the Auto-Retractable Safety IV Catheter. The world market for SEMDs was projected to exceed $1.6 billion last year and is forecast to maintain a 20% annual growth rate in the near term.
In the United States, the safety syringe market is expected to generate approximately $693 million in revenues in 2006, representing 66% of the total needles and syringes market. The Theta Report estimated the number of needles and syringes sold in the U.S. and international market combined should exceed 20 billion units in 2006.
For more information on Maxxon, please go to http://www.maxxoninc.com .
Safe Harbor
Forward-looking statements made in this release are made pursuant to the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made by Maxxon Inc. are not a guarantee of future performance. This news release includes forward-looking statements, including with respect to the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties and events that may be beyond the control of Maxxon Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain and successfully complete projects, and changes in products and competition.
For investor relations information, contact: Gabe Sandler Sandler Communications, Inc. Phone: 866-772-0118 Email: info@sandlercommunications.com
Maxxon Inc.
CONTACT: Gabe Sandler of Sandler Communications, Inc., +1-866-772-0118, orinfo@sandlercommunications.com , for Maxxon Inc.
Web site: http://www.maxxoninc.com/